Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8
Primary Industries
- Drugs
- Therapeutic
- Pharmaceuticals
- Disease
- cardiac
- Diabetes Treatment
- Delivery
- Biotechnology
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 3783
License Grant
The Licensor licensed US and Canadian rights to Glumetza to the Licensee in 2002.
License Property
Glumetza (metformin hydrochloride extended release tablets) is a once-daily treatment for adults with type 2 diabetes. The Licensor received a license fee payment from the Licensee under our original license agreement following FDA approval of Glumetza. Glumetza® (metformin hydrochloride extended release tablets) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Field of Use
Pursuant to the Amended and Restated License Agreement, the Licensee has an exclusive license in Canada to manufacture and market the 500mg Glumetza, and the1000mg Glumetz, if that formulation is approved and marketed in Canada.
IPSCIO Record ID: 4282
License Grant
The Licensor entered into a commercialization agreement with the Licensee granting exclusive rights to manufacture and commercialize Glumetza in the United States.
The Licensor hereby grants to the Licensee an exclusive, royalty-free right and license to use the Depomed Trademarks solely in connection with Commercializing the Products in the Territory.
License Property
Under the commercialization agreement, the Licensor transitioned to the Licensee responsibility for manufacturing, distribution, pharmacovigilance and regulatory affairs.
The Licensor ceased shipments of Glumetza in August 2011 and the Licensee began distributing and recording product sales on shipments of Glumetza in September 2011.
The Licensee will continue to be responsible at its expense for advertising and promotional marketing activities for Glumetza.
The Licensee has the exclusive right to commercialize authorized generic versions of the Glumetza products and will not pay additional sales milestones to the Licensor.
“Depomed Trademarks†means (a) Glumetza® (the “Depomed Product Trademarkâ€), (b)Acuform® (the “Depomed Technology Trademarkâ€), and (c) Depomed® (the “Depomed Corporate Trademarkâ€).
Field of Use
Glumetza (metformin hydrochloride extended release tablets) is used for Diabetes.
IPSCIO Record ID: 6611
License Grant
Licensor hereby grants to Licensee an exclusive License to market the 1000mg Gl in the United States, and an exclusive License to the Glumetza trademark in the United States for the purpose of marketing Glumetza.
License Property
The 1000mg Glumetza is purchased exclusively from Biovail under the supply Agreement, subject to back-up manufacturing rights in our favor.
Field of Use
Glumetza (Metformin) is used alone or with other medications, including insulin, to treat type 2 diabetes.
IPSCIO Record ID: 3055
License Grant
The Licensee entered into a distribution and License Agreement with the Licensors for exclusive rights to manufacture and commercialize the prescription product Cycloset® (bromocriptine mesylate) tablets in the U.S. Cycloset is approved by the U.S. Food and Drug Administration as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus both as mono-therapy and in combination with other diabetes medications. The Licensee is required to commence commercialization activities for Cycloset in the fourth quarter of 2010.
Field of Use
Cycloset is approved as an adjunct to diet and exercise to improve glycemic control in Type II diabetes mellitus.
IPSCIO Record ID: 153529
License Grant
Licensor grants the exclusive right and license to market, promote, sell and distribute the Products listed in the Territories.
License Property
Licensor products are Metformin Extended Release, Lovastatin Extended Release and Omeprazole Delayed Release Capsules.
Lovastatin Extended Release is used along with a proper diet to help lower 'bad' cholesterol and fats? (such as LDL, triglycerides) and raise 'good' cholesterol (HDL?) in the blood.
Metformin and extended release metformin are used in type 2 diabetes to improve glycemic control in combination with diet and exercise.
Omeprazole Delayed-Release Capsules is used to treat or prevent GI (gastrointestinal) ulcers caused by infection.
Field of Use
Lovastatin is a statin drug, used for lowering cholesterol in those with hypercholesterolemia to reduce risk of cardiovascular disease.
IPSCIO Record ID: 209493
License Grant
In consideration of Licensors performance, to date, under the Agreement and its agreement herein to relinquish all of its rights in and to the Licensee Products.
License Property
The rights relate to the sale of Metformin in the United States. Metformin is the first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight.
Field of Use
This agreement is for the pharmaceutical industry.
Metformin is used in the treatment of diabetes.
IPSCIO Record ID: 26162
License Grant
Pursuant to the development and license agreement, licensee has an exclusive, worldwide license to the technology for the development and commercialization of injectable extended-release formulations of exendins and other related compounds.
License Property
Two U.S. pharmaceutical companies are collaborating on the development of exenatide once weekly for the treatment of type 2 diabetes. Exenatide once weekly is an injectable formulation of Licensee’s Byetta® (exenatide). Byetta is an injection administered twice daily. Diabetes is a disease in which the body does not produce or properly use insulin. Diabetes can result in serious health complications, including cardiovascular, kidney and nerve disease. Byetta was approved by the FDA in April 2005 as adjunctive therapy to improve blood sugar control in patients with type 2 diabetes who have not achieved adequate control on metformin and/or a sulfonylurea, which are commonly used oral diabetes medications. In December 2006, the FDA approved Byetta as an add-on therapy for people with type 2 diabetes unable to achieve adequate glucose control on thiazolidinediones, a class of diabetes medications. Licensee has an agreement with another pharmaceutical company for the development and commercialization of exenatide, including exenatide once weekly. Exenatide once weekly is being developed with the goal of providing patients with an effective and more patient-friendly treatment option.
Field of Use
The rights granted apply to the medical industry.
IPSCIO Record ID: 1313
License Grant
The Settlement Agreement provides for, among other things, the termination of the Collaboration Agreement, by and between the two parties, dated September 19, 2002, as amended (the “Collaboration Agreementâ€), pursuant to which the two parties collaborated in the global development and commercialization of exenatide, including the twice-daily version of exenatide, Byette® (exenatide) injection, and sustained-release formulations, such as Bydureonâ„¢ (exenatide extended-release for injectable suspension) (for diabetes), which has been approved in the European Union and is currently under review by the United States Food and Drug Administration (the “FDAâ€). The Settlement Agreement also provides for the full and final settlement and resolution of certain outstanding claims by licensee.
License Property
Bydureon is an injectable prescription medicine that may improve blood sugar (glucose) in adults with type 2 diabetes mellitus, and should be used along with diet and exercise. Bydureon is not recommended as the first medication to treat diabetes.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
